300406 Beijing Strong Biotechnologies, Inc.
- 17.31
- +0.10+0.58%
Beijing Strong Biotechnologies, Inc. News
Express News | Beijing Strong Biotechnologies, Inc.: Recently received a patent certificate issued by the National Intellectual Property Office.
Zhitong A Share Sale Restriction Release List|May 17
According to the Zhitong Finance App, the ban on restricted shares of 13 listed companies was lifted on May 17, with a total market value of about 20.077 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of unbanned shares Shenzhen Sanda A000032, original shareholders placed 493 million, Lutai A000726 share incentives, 6.795 million, Guohai Securities 000750 issued additional A shares, original shareholders placed 352 million, Nasda002180 equity incentives, restricted circulation 1,154 million Jiujiang Biotech 300406 share incentives to limit sales and circulation 4076 million
Top 9 Convertible Bonds: Stock conversion will resume on May 7
Beijing Jiuqiang Biotechnology Co., Ltd. announced that “Jiuqiang Convertible Bonds” will resume share conversion on May 7, 2024, the first trading day after the share registration date for this equity distribution.
Jiuqiang Biotech (300406.SZ) announced first-quarter results, net profit of 121 million yuan, an increase of 8.67%
Jiuqiang Biotech (300406.SZ) released its report for the first quarter of 2024, achieving operating income of 3.9 during the reporting period...
Jiuqiang Biotech (300406) 2024 Quarterly Report Review: Further Improving Profitability, Platform Construction Continues to Advance
Incident: The company released its 2024 quarterly report. In the first quarter of 2024, the company achieved operating income of 394 million yuan, an increase of 5.49% over the previous year; achieved net profit of 121 million yuan, an increase of 8.67% over the previous year; realized deductions
Jiuqiang Convertible Bonds: The conversion price was adjusted from 17.55 yuan/share to 17.35 yuan/share
Beijing Jiuqiang Biotechnology Co., Ltd. announced that the conversion price of “Jiuqiang Convertible Bonds” will be adjusted from 17.55 yuan/share to 17.35 yuan/share. The adjusted share conversion price will take effect from May 7, 2024 (equity distribution exclusion date).
Jiuqiang Biotech: “Jiujiang Bonds Transfer” suspends share conversion during the implementation of equity distribution
Beijing Jiuqiang Biotechnology Co., Ltd. announced that the company will soon implement the company's 2023 equity distribution. From April 24, 2023 to the 2023 equity distribution share registration date, “Jiuqiang Bonds Transfer” will suspend share conversion and resume share conversion from the first trading day after the 2023 equity distribution share registration date.
Express News | Jiuqiang Biology: Rh blood typing card (microcolumn gel method) obtained medical device registration certificate
Jiuqiang Biotech (300406.SZ) obtained a medical device registration certificate
Jiuqiang Biotech (300406.SZ) announced that the company received the “Medical Device Registration...” issued by the State Drug Administration
Pacific released a research report on April 8, stating that Jiujiang Biotech (300406.SZ) was given a purchase rating. The main reasons for the rating include: 1) full recovery of outpatient and surgical volumes in medical institutions, driving growth in b
Pacific released a research report on April 8, stating that Jiujiang Biotech (300406.SZ) was given a purchase rating. The main reasons for the rating include: 1) full recovery of outpatient and surgical volumes in medical institutions, driving growth in biochemical and pathologic reagent sales; 2) cooperating with EGI to explore overseas and deepen the global layout strategy; 3) Sinopharm's multi-faceted empowerment to vigorously develop the pathology sector; 4) sales expenses dropped significantly, and the overall net margin increased by 3.87 pct. (Mainichi Keizai Shimbun)
Jiuqiang Biotech (300406) Annual Report Review: Steady Performance Growth, Sinopharm Empowers Marketing Efficiency
Incident: On March 30, 2024, the company released its 2023 annual report: achieved annual revenue of 1,742 billion yuan, an increase of 15.27% over the previous year; net profit to mother was 524 million yuan, an increase of 34 million yuan over the previous year
Zhongtai Securities: Q1 results are about to be implemented, gradually focus on the pharmaceutical sector and individual stocks with improved Q2 performance
Zhongtai Securities said that at present, the overall market is still at a relative bottom. After experiencing a long-term correction, the pharmaceutical sector is also at multiple bottoms in terms of fundamentals, policies, and capital, and is firmly optimistic about the pharmaceutical sector market throughout the year.
Jiuqiang Biotech (300406) 2023 Report Review: Strong 23Q4 performance, Sinopharm continues to advance
Event: The company announced its 2023 results, with revenue of 1,742 billion yuan in 2023, up 15.27% year on year; net profit to mother was 524 million yuan, up 34.60% year on year. Net profit not attributable to mother 5.1
Jiuqiang Biotech (300406): Performance is in line with expectations and continues to be optimistic about pathology business+Sinopharm empowerment
Incident: Recently, the company released its 2023 annual report. In 2023, the company achieved operating income of 1,742 billion yuan, a year-on-year increase of 15.27%, and net profit to mother of 524 million yuan, an increase of 34.60% year-on-year, after deducting non-net profit
Jiuqiang Biotech (300406.SZ): Net profit in 2023 increased 34.6% year-on-year, and plans to distribute 2 yuan for 10 shares
Gelonghui March 29 丨 Jiuqiang Biotech (300406.SZ) released its 2023 annual report. The company achieved operating income of 174,16.267 million yuan, an increase of 15.27% over the previous year; total profit of 593.5546 million yuan, an increase of 32.09% over the previous year; the total equity of owners attributable to shareholders of listed companies was 372,459.19 yuan, an increase of 13.86% over the previous year; and net profit attributable to shareholders of listed companies was 52,374.28 yuan, an increase of 34.60% over the previous year. A cash dividend of 2 yuan is distributed to all shareholders for every 10 shares.
Jiuqiang Biotech (300406.SZ) subsidiary completed 24 Class I medical device registrations
Jiuqiang Biotech (300406.SZ) announced that Fuzhou Maixin Biotechnology Development Co., Ltd., a wholly-owned subsidiary of the company, recently...
Express News | Jiuqiang Biotech: China Pharmaceutical Investment Co., Ltd., the largest shareholder, promised not to reduce its holdings within 6 months
Jiuqiang Biotech (300406)'s wholly-owned subsidiary invests abroad in Xiamen Longjin Biotechnology Co., Ltd. announcement comment: Acquiring part of Longjin Biotech's shares to build a platform-based enterprise
Incident: The company recently announced that its wholly-owned subsidiary Maixin Biotech subscribed to Longjin Biotech's additional registered capital of 6 million yuan with 32 million yuan, and the remaining portion was included in the capital reserve. After the transaction was completed, Maxine Biotech held Longjin Biotech 25.21
Jiuqiang Biotech (300406.SZ) plans to spend 32 million yuan to subscribe for 25.21% of Longjin Biotech's shares to supplement the product pipeline
Jiuqiang Biotech (300406.SZ) announced that Fuzhou Maixin Biotechnology Development Co., Ltd., a wholly-owned subsidiary of the company...
Jiuqiang Biotech (300406): Acquired leading FISH track company Longjin Biotech to jointly enhance overall competitiveness
Incident: The company issued an announcement. Maixin Biotech, a wholly-owned subsidiary, plans to purchase Longjin Biotech with an additional registered capital of RMB 6 million with its own funds. Longjin Biotech's valuation before this investment was RMB
Analysis
Price Target
No Data
